Analysis of the ACE Inhibitors Market: Industry Structure, Emerging Trends, and Key Player Overview

The ACE inhibitors market is set to experience significant growth in the coming years, driven by advancements in medical treatment and expanding healthcare access. With increasing demand for tailored therapies and digital health integration, this segment of the pharmaceutical industry is evolving rapidly. Let's explore the market's value projections, leading companies, emerging trends, and key segments shaping its future.

Projected Market Value and Growth Rate of the ACE Inhibitors Market
The ACE inhibitors market is anticipated to expand steadily, reaching a valuation of $10.11 billion by 2030. This represents a compound annual growth rate (CAGR) of 6.5% during the forecast period. Factors contributing to this growth include a rising preference for personalized medicine, wider adoption of digital health technologies, growth in emerging markets, development of new ACE inhibitor combinations, and an increase in home healthcare services. Key market trends expected to influence this expansion are personalized hypertension management, telemedicine and remote patient monitoring, advancements in combination therapies, a surge in generic ACE inhibitors, and the broadening scope of home healthcare solutions.

Download a free sample of the ace inhibitors market sample:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10671&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Top Companies Leading the ACE Inhibitors Market
Several major pharmaceutical players hold substantial influence in the ACE inhibitors market. Some of the prominent companies include Pfizer Inc., Novartis AG, Johnson & Johnson Private Limited, Merck KGaA, Sanofi S.A., Bayer AG, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Co., Takeda Pharmaceuticals Company, Daiichi Sankyo Company Ltd., Endo International plc, Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim, Bausch Health Companies Inc., Dr. Reddy's Laboratories, Abbott Laboratories, Eli Lilly and Company, Cipla Limited, GlaxoSmithKline plc, Cadila Healthcare Limited, AbbVie Inc., Sandoz Group AG, Accord Healthcare Ltd., AstraZeneca plc, Lupin Limited, Macleods Pharmaceuticals Limited, Zydus Lifescience Ltd., and Apotex Inc.

AstraZeneca's Strategic Acquisition in the ACE Inhibitors Market
In January 2023, AstraZeneca, a UK-based pharmaceutical firm, acquired CinCor Pharma for $1.3 billion. This strategic move is aimed at expanding AstraZeneca's portfolio of aldosterone synthase inhibitors (ASI), which are used for lowering blood pressure in patients with treatment-resistant hypertension. CinCor Pharma, based in the US, is a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting resistant and uncontrolled hypertension as well as chronic kidney disease. This acquisition is expected to boost AstraZeneca's position in these specialized treatment areas.

View the full ace inhibitors market report:
https://www.thebusinessresearchcompany.com/report/ace-inhibitors-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Emerging Trends Highlighting Generics in the ACE Inhibitors Market
Leading companies in the ACE inhibitors market are increasingly concentrating on launching generic versions of drugs to strengthen their market competitiveness. Generic medications contain the same active ingredients, dosage, safety profile, and efficacy as their branded counterparts but are typically more affordable once patents expire. For example, in August 2023, Pharmascience Inc., a Canadian pharmaceutical company, introduced pms-PERINDOPRIL-INDAPAMIDE. This generic medication is designed for the initial treatment of mild to moderate essential hypertension in adults and combines perindopril erbumine, an ACE inhibitor that relaxes blood vessels, with indapamide, a diuretic that helps remove excess fluid and sodium from the body. This combination works synergistically to effectively reduce blood pressure across diverse patient groups. The medication is available in multiple dosage forms, offering flexibility to meet patient needs.

Detailed Segment Analysis of the ACE Inhibitors Market
This report categorizes the ACE inhibitors market into several key segments to provide a comprehensive understanding of its growth drivers:

1) By Type:
- Sulfhydryl-containing Agents
- Dicarboxylate-containing Agents
- Phosphonate-containing Agents

2) By Drug:
- Ramipril
- Enalapril
- Benazepril
- Fosinopril
- Captopril
- Moexipril
- Other Drugs

3) By Dosage Form:
- Oral Tablets
- Oral Solutions

4) By Application:
- Heart Failure
- Chronic Kidney Disease
- Hypertension
- Diabetes
- Heart Attack
- Other Applications

5) By End-Users:
- Hospitals
- Online Drug Stores
- Other End-Users

Subsegments further detail the types of agents:
- Sulfhydryl-containing Agents include Captopril and Zofenopril
- Dicarboxylate-containing Agents cover Enalapril, Lisinopril, Ramipril, Quinapril, Benazepril, Perindopril
- Phosphonate-containing Agents consist of Fosinopril, Fosinopril Sodium, and Fosinopril Calcium

This segmentation highlights the diverse drug types, applications, and delivery forms contributing to the ACE inhibitors market's steady expansion.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.